Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

TORRANCE, Calif., May 13, 2022 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.

Recent Highlights

April 2022: Announced the launch of an innovative, full-service telehealth solution (https://www.endarirx.com/ask-physician) with…

Source link

Tags: Emmaus Life Sciences Inc.

Insights on the Aseptic Pharma Processing Global Market to

Letterkenny to celebrate Africa Day

RelatedPosts

StanChart in talks to sell aviation finance unit to AviLease … – Reuters

Antares Capital Expands Coverage into Europe with Appointment of … – WSIL TV

Government finalising big change for businesses in South Africa – BusinessTech

Wafer Dicing Saws Market Outlook- Global Industry Size, Share, Trends, Growth Opportunities, Forecasts by Types, Applications, Countries, and Companies, 2023 to 2030 – Yahoo Finance

Latest Post

Africa has technology and innovation to achieve zero hunger … – African Development Bank

GITEX Africa: Huawei Leverages New Solutions for a More Digital … – Morocco World News

Oil and Gas Additive Manufacturing Market Growth, Share, Size, Performance And SWOT Analysis 2023 -2029 – openPR

Heard on the Street: Europe's Economy May Be Stronger Than It … – The Wall Street Journal

Australian children stranded in Syria sue government to push for … – Middle East Eye

Subscribe to Our Newsletter

Browse by Category-

Share us